This post relates to the Vioxx litigation, in which Beck’s firm is involved. You therefore can’t blame Beck for this post; it’s being written entirely by Herrmann.
We’ve previously posted about the headaches caused when unrelated plaintiffs join their claims in a single complaint.
In the Vioxx litigation, Judge Fallon had originally permitted unrelated plaintiffs
Your humble scribes will be busy this fall.
One of them, Herrmann, will be speaking at the ACI’s “Defending Fraud Claims in Consumer Class Actions Conference” in New York City on October 15 and 16, the American Society for Pharmacy Law’s “18th Annual Pharmacy Law Seminar” at Loew’s Coronado Bay Resort in Coronado, California, on
It certainly didn’t take long.
Back in late July we posted about the extraordinarily restrictive view of Vaccine Act (and indeed of all) preemption taken in Ferrari v. American Home Products Corp., 2007 WL1933129 (Ga. App. July 5, 2007).
In our view Ferrari had taken the presumption against preemption to an “unprecedented” extreme –
This guest post was written by David Booth Alden. Mr. Alden is a partner resident in the Cleveland office of Jones Day. This post is entirely his work. It of course represents only his views, and not the views of his clients or firm.
The privilege as applied to in-house attorneys
Some in-house
One of your humble scribes, Mark Herrmann, is changing locations. After 18 years at Jones Day’s Cleveland office, he has moved to the Chicago office as of today, September 4.
(Isn’t the internet wonderful? You never even knew he was in Cleveland, did you?)
This won’t affect the blog in any way. The worldwide